Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jun 1;221(2):215-21.
doi: 10.1016/j.taap.2007.03.009. Epub 2007 Mar 23.

Involvement of CYP 2E1 enzyme in ovotoxicity caused by 4-vinylcyclohexene and its metabolites

Affiliations

Involvement of CYP 2E1 enzyme in ovotoxicity caused by 4-vinylcyclohexene and its metabolites

Kathila S Rajapaksa et al. Toxicol Appl Pharmacol. .

Abstract

4-Vinylcyclohexene (VCH) is bioactivated by hepatic CYP 2A and 2B to a monoepoxide (VCM) and subsequently to an ovotoxic diepoxide metabolite (VCD). Studies suggest that the ovary can directly bioactivate VCH via CYP 2E1. The current study was designed to evaluate the role of ovarian CYP 2E1 in VCM-induced ovotoxicity. Postnatal day 4 B6C3F(1) and CYP 2E1 wild-type (+/+) and null (-/-) mouse ovaries were cultured (15 days) with VCD (30 microM), 1,2-VCM (125-1000 microM), or vehicle. Twenty-eight days female CYP 2E1 +/+ and -/- mice were dosed daily (15 days; ip) with VCH, 1,2-VCM, VCD or vehicle. Following culture or in vivo dosing, ovaries were histologically evaluated. In culture, VCD decreased (p<0.05) primordial and primary follicles in ovaries from all three groups of mice. 1,2-VCM decreased (p<0.05) primordial follicles in B6C3F(1) and CYP 2E1 +/+ ovaries, but not in CYP 2E1 -/- ovaries in culture. 1,2-VCM did not affect primary follicles in any group of mouse ovaries. Conversely, following in vivo dosing, primordial and primary follicles were reduced (p<0.05) by VCD and VCM in CYP2E1 +/+ and -/-, and by VCH in +/+ mice. The data demonstrate that, whereas in vitro ovarian bioactivation of VCM requires CYP 2E1 enzyme, in vivo CYP 2E1 plays a minimal role. Thus, the findings support that hepatic metabolism dominates the contribution made by the ovary in bioactivation of VCM to its ovotoxic metabolite, VCD. This study also demonstrates the use of a novel ovarian culture system to evaluate ovary-specific metabolism of xenobiotics.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement There are no conflicts of interest that inappropriately influence the above work submitted.

Figures

Figure 1
Figure 1. Proposed scheme for hepatic bioactivation of VCH
The parent compound, VCH, is bioactivated by cytochrome P450 (CYP 450) to form either 1,2 or 7,8-monoepoxide metabolites. These intermediate metabolites further undergo bioactivation by CYP 450 enzymes to form the ultimate ovotoxic diepoxide metabolite (VCD).
Figure 2
Figure 2. VCD - induced ovotoxicity in various strains of mouse ovaries in culture
Ovaries from PND4 B6C3F1, CYP 2E1 +/+, or CYP 2E1 -/- mice were cultured with medium control or 30μM VCD for 15d. Following incubation, ovaries were collected, and processed for histological evaluation as described in materials and methods. Healthy (A) primordial, and (B) primary follicles were classified and counted. Values are mean ± SE total follicles counted/ovary, n=5; different letters differ (p<0.05) from one another within each follicle type.
Figure 3
Figure 3. Involvement of CYP 2E1 in 1,2-VCM - induced ovotoxicity in ovarian cultures
Ovaries from PND4 B6C3F1, CYP 2E1 +/+ or -/- mice were cultured with medium control or 1,2-VCM (125, 250, 500, 750, or 1000 μM) for 15d. Following incubation, ovaries were collected, and processed for histological evaluation as described in materials and methods. Healthy (A) primordial, and (B) primary follicles were classified and counted. Values are mean ± SE total follicles counted/ovary, n=5; different letters differ (p<0.05) from one another within each follicle type.
Figure 4
Figure 4. Effect of in vitro VCM and VCD exposure on ovarian morphology
Ovaries from PND4 CYP 2E1 +/+ (A,C and E) and -/- (B,D and F) mice were cultured with control medium (A and B), 1,2-VCM (1000 μM; C and D), or 30μM VCD (E and F) for 15d. Following incubation, ovaries were collected, and processed for histological evaluation as described in materials and methods. All images were captured with a 40X objective lens. Bar represents 20μm.
Figure 5
Figure 5. Involvement of CYP 2E1 in VCH – induced ovotoxicity
Female CYP 2E1 +/+ and -/- mice were treated with repeated daily doses (i.p.) of sesame oil (control), VCH (7.4mmol/kg/d), 1,2-VCM (2.74mmol/kg/d), or VCD (0.57mmol/kg/d) for 15d. 4h following the final dose ovaries were collected, and processed for histological evaluation as described in materials and methods. Healthy (A) primordial, (B) primary, (C) secondary, and (D) antral follicles were classified and counted. Values are mean ± SE total follicles counted/ovary, n=5; different letters differ (p<0.05) from one another within each follicle type.

Similar articles

Cited by

References

    1. Cannady EA, Dyer CA, Christian PJ, Sipes IG, Hoyer PB. Expression and activity of microsomal expoxide hydrolase in follicles isolated from mouse ovaries. Toxicol Sci. 2002;68:24–31. - PubMed
    1. Cannady EA, Dyer CA, Christian PJ, Sipes IG, Hoyer PB. Expression and activity of cytochrome P450 2E1, 2A, and 2B in the mouse ovary: The effect of 4-vinylcyclohexene and its diepoxide metabolite. Toxicol Sci. 2003;73:423–430. - PubMed
    1. Chhabra RS, Elwell MR, Peters A. Toxicity of 4-vinyl-1-cyclohexene diepoxide after 13 weeks of dermal and oral exposure in rats and mice. Fundam Appl Toxicol. 1990;14:745–751. - PubMed
    1. Devine PJ, Sipes IG, Skinner MK, Hoyer PB. Characterization of a rat in vitro ovarian culture system to study the ovarian toxicant 4-vinylcyclohexene diepoxide. Toxicol Appl Pharmacol. 2002a;184:107–115. - PubMed
    1. Devine PJ, Rajapaksa KS, Hoyer PB. In vitro ovarian tissue and organ culture: a review. Front Biosci. 2002b;1:d1979–1989. - PubMed

Publication types